Literature DB >> 35769797

Impact of Type of Treatment Center and Access to Care on Mortality and Survival for Skull Base Chordoma and Chondrosarcoma.

Adam L Holtzman1, James E Bates1, Christopher G Morris1, Michael S Rutenberg1, Daniel J Indelicato1, Daryoush Tavanaiepour2, William M Mendenhall1.   

Abstract

Introduction  In adults with skull base chordoma or chondrosarcoma, the impact of treatment center and access to care have not been well described in regard to perioperative mortality and survival. Methods  A query of the National Cancer Database (NCDB) and review of 1,102 adults-488 with chordomas and 614 with chondrosarcomas-was performed. The Kaplan-Meier's product limit method and chi-square analysis, respectively, assessed overall survival and 30-day (30D) and 90-day (90D) mortalities. Results  For 925 patients who had surgery and available mortality data, the 30D and 90D mortality rates were 0.9 and 1.5%. Lower education level ( p  = 0.0185) and treatment at a nonacademic facility ( p  = 0.016) were associated with increased risk of 90-day mortality. Median follow-up was 52 months and analysis was dichotomized by histology. For those with skull base chordoma, patients from a larger metro size ( p  = 0.002), age below the median 52 years ( p ≤ 0.001), and private insurance (<0.001) were associated with prolonged survival, whereas for skull base chondrosarcoma, the factors were treatment at an academic medical center ( p  = 0.001), high-volume center ( p  = 0.007), age below the median 52 years ( p ≤ 0.001), higher income ( p  = 0.043), higher education ( p  = 0.017), and private insurance ( p ≤ 0.001). Comparing high-, medium-, and low-volume centers, high-volume centers were most likely to be academic, deliver radiotherapy, escalate doses >70 Gy, and utilize proton radiotherapy consistent across both disease subsets. Conclusion  Higher educational attainment and treatment at an academic facility were associated with decreased 90D mortality for patients with skull base chordoma and chondrosarcoma. For those with skull base chordoma, larger metro size, younger age, and private insurance were associated with prolonged survival; for those with chondrosarcoma, it was treatment at a high-volume or academic medical center, younger age, higher income or education, and private insurance. Thieme. All rights reserved.

Entities:  

Keywords:  chondrosarcoma; chordoma; skull base tumors

Year:  2021        PMID: 35769797      PMCID: PMC9236745          DOI: 10.1055/s-0040-1722228

Source DB:  PubMed          Journal:  J Neurol Surg B Skull Base        ISSN: 2193-634X


  16 in total

1.  Endoscopic endonasal approach for resection of cranial base chordomas: outcomes and learning curve.

Authors:  Maria Koutourousiou; Paul A Gardner; Matthew J Tormenti; Stephanie L Henry; Susan T Stefko; Amin B Kassam; Juan C Fernandez-Miranda; Carl H Snyderman
Journal:  Neurosurgery       Date:  2012-09       Impact factor: 4.654

Review 2.  Proton therapy for skull base tumors: A review of clinical outcomes for chordomas and chondrosarcomas.

Authors:  Catherine E Mercado; Adam L Holtzman; Ronny Rotondo; Michael S Rutenberg; William M Mendenhall
Journal:  Head Neck       Date:  2018-12-07       Impact factor: 3.147

Review 3.  Proton therapy for tumors of the skull base.

Authors:  J E Munzenrider; N J Liebsch
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

4.  A Prospective Outcomes Study of Proton Therapy for Chordomas and Chondrosarcomas of the Spine.

Authors:  Daniel J Indelicato; Ronny L Rotondo; Dustin Begosh-Mayne; Mark T Scarborough; C Parker Gibbs; Christopher G Morris; William M Mendenhall
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-05-01       Impact factor: 7.038

5.  Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study.

Authors:  Adam L Holtzman; Ronny L Rotondo; Michael S Rutenberg; Daniel J Indelicato; Catherine E Mercado; Dinesh Rao; Daryoush Tavanaiepour; Christopher G Morris; Debbie Louis; Stella Flampouri; William M Mendenhall
Journal:  J Neurooncol       Date:  2019-03-02       Impact factor: 4.130

6.  The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base.

Authors:  Russell F Palm; Daniel E Oliver; George Q Yang; Yazan Abuodeh; Arash O Naghavi; Peter A S Johnstone
Journal:  Cancer       Date:  2019-01-14       Impact factor: 6.860

7.  Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.

Authors:  Leif-Erik Bohman; Matthew Koch; Robert L Bailey; Michelle Alonso-Basanta; John Y K Lee
Journal:  World Neurosurg       Date:  2014-07-05       Impact factor: 2.104

8.  Efficacy and Safety of Adjuvant Proton Therapy Combined With Surgery for Chondrosarcoma of the Skull Base: A Retrospective, Population-Based Study.

Authors:  Loïc Feuvret; Stefano Bracci; Valentin Calugaru; Stéphanie Bolle; Hamid Mammar; Ludovic De Marzi; Damien Bresson; Jean-Louis Habrand; Jean-Jacques Mazeron; Rémi Dendale; Georges Noël
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-12-17       Impact factor: 7.038

9.  Endoscopic Resection Followed by Proton Therapy With Pencil Beam Scanning for Skull Base Tumors.

Authors:  Jonathan E Leeman; Nancy Y Lee; Ying Zhou; Brian Neal; Kevin Sine; Viviane Tabar; Marc A Cohen
Journal:  Laryngoscope       Date:  2018-09-12       Impact factor: 3.325

10.  Surgeon volume and operative mortality in the United States.

Authors:  John D Birkmeyer; Therese A Stukel; Andrea E Siewers; Philip P Goodney; David E Wennberg; F Lee Lucas
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.